Healthcare Wire Texas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.

Press releases published on October 14, 2026

11 hours ago

iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch

Indeterminate GlobeNewswire

11 hours ago

Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study

Indeterminate GlobeNewswire

11 hours ago

Bluesight Launches Prism Assistant in PrivacyPro, Bringing AI-Powered Investigations to Patient Privacy Teams

Indeterminate GlobeNewswire

11 hours ago

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

Indeterminate GlobeNewswire

11 hours ago

Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026

Indeterminate GlobeNewswire

11 hours ago

Rhea’s Factory Partners with Niagara Bottling on Industrial Validation of Enzymatic PET Recycling Through U.S. Department of Energy Program

Indeterminate GlobeNewswire

12 hours ago

TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

Indeterminate GlobeNewswire

12 hours ago

Purespring Therapeutics to present new data on pipeline progress in Alport Syndrome at the American Society of Nephrology (ASN) Kidney Week 2026

Indeterminate GlobeNewswire

12 hours ago

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

Indeterminate GlobeNewswire

12 hours ago

BreathiZen Introduces BreathiZen Spray With Mullein Leaf Extract, Ginger Root Extract, Bromelain, and Organic Lemon Extract 60 ml

Indeterminate GlobeNewswire

12 hours ago

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

Indeterminate GlobeNewswire

12 hours ago

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

Indeterminate GlobeNewswire

12 hours ago

Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer

Indeterminate GlobeNewswire

12 hours ago

Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome

Indeterminate GlobeNewswire

12 hours ago

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

Indeterminate GlobeNewswire

12 hours ago

Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and Advances Huntington's Disease Franchise

Indeterminate GlobeNewswire

12 hours ago

Elion Therapeutics Expands Pipeline with Exclusive Global License to Inhaled Antifungal for Immunocompromised Patients

Indeterminate GlobeNewswire

12 hours ago

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

Indeterminate GlobeNewswire

13 hours ago

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Indeterminate GlobeNewswire

13 hours ago

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Indeterminate GlobeNewswire